文献速递胸部肿瘤

帕博利珠单抗联合仑伐替尼二线治疗胸膜间皮瘤:PEMMELA研究队列2

Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study.
PubMed 文献 · Lancet Oncol · 2025-01-01

PEMMELA队列2是一项单臂2期研究,评估帕博利珠单抗联合仑伐替尼在纳武利尤单抗联合伊匹木单抗一线治疗后进展的胸膜间皮瘤患者中的疗效与安全性。20例可评估患者中12例(60%,95%CI 36-81%)客观缓解,但70%发生3-4级治疗相关不良事件。研究达到主要终点,提示该联合方案有前景但毒性显著。

要点

  • 纳武利尤单抗联合伊匹木单抗进展后,帕博利珠单抗联合仑伐替尼客观缓解率达60%。
  • 3-4级治疗相关不良事件发生率为70%,最常见为高血压和乏力。
  • 45%患者需至少一次剂量减少,10%因毒性终止治疗。

核心结论

  • 帕博利珠单抗联合仑伐替尼在纳武利尤单抗联合伊匹木单抗治疗后进展的胸膜间皮瘤患者中显示高临床活性,但毒性显著。

研究设计与样本

  • PEMMELA为荷兰癌症研究所开展的前瞻性、单中心、单臂、开放标签、研究者发起的2期试验。
  • 队列2纳入20例既往纳武利尤单抗联合伊匹木单抗治疗后进展的胸膜间皮瘤患者,接受帕博利珠单抗200 mg每3周静脉联合仑伐替尼20 mg每日口服,最长2年。
  • 主要终点为研究者评估的客观缓解率,安全性分析集为至少接受一周期治疗的所有患者。

主要发现

  • 20例中14例(70%)发生3-4级治疗相关不良事件,最常见3级事件为高血压(5例[25%])和乏力包括不适(4例[20%])。
  • 7例患者发生10起治疗相关严重不良事件,9例(45%)需至少一次剂量减少,2例(10%)因毒性终止治疗,无治疗相关死亡。

临床怎么用

  • 对于一线纳武利尤单抗联合伊匹木单抗治疗后进展的胸膜间皮瘤患者,帕博利珠单抗联合仑伐替尼可作为候选二线方案,但需密切监测高血压和乏力等毒性。

局限性

  • 单中心、单臂、小样本2期研究,结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pembrolizumab (anti-PD-1 antibody) plus lenvatinib (multityrosine kinase inhibitor) showed high clinical activity in PEMMELA cohort 1 in patients with pleural mesothelioma pre-treated with platinum-based chemotherapy. This study (cohort 2) aimed to investigate the clinical activity of this combination in patients with pleural mesothelioma who progressed after first-line nivolumab plus ipilimumab. METHODS: PEMMELA is a prospective, single-centre, single-arm, open-label, investigator-initiated phase 2 trial, done at the Netherlands Cancer Institute, Amsterdam, the Netherlands. Cohort 2 included patients aged 18 years and older with histologically confirmed pleural mesothelioma, an Eastern Cooperative Oncology Group performance status 0-1, and measurable disease according to the modified Response Evaluation Criteria in Solid Tumors for mesothelioma version 1.1, who progressed after treatment with nivolumab plus ipilimumab. Pembrolizumab (200 mg every 3 weeks intravenously) plus lenvatinib (20 mg orally daily) was administered for up to 2 years, or until disease progression, or unacceptable toxicity. The primary endpoint was objective response rate assessed by the local investigator. All patients who had received at least one cycle of pembrolizumab plus lenvatinib and had their disease evaluated were considered evaluable for the primary endpoint. All patients who received at least one cycle of the study treatment were included in the safety analysis set. Patients were not involved in study design. This study is registered with ClinicalTrials.gov (NCT04287829), and is complete. FINDINGS: Between Dec 14, 2022, and March 5, 2023, 24 patients were screened, of whom 20 were enrolled and received at least one cycle of pembrolizumab plus lenvatinib. Of these 20 patients, 17 patients (85%) were male and three (15%) were female. At data cutoff (Sept 1, 2024), with a median follow-up of 11·9 months (IQR 10·8-15·8), 12 (60%, 95% CI 36-81%) of 20 patients had an objective response. 14 (70%) of 20 patients developed grade 3 or 4 treatment-related adverse events, of which most common grade 3 events were hypertension (five patients [25%]) and fatigue including malaise (four patients [20%]). Ten treatment-related serious adverse events were observed in seven patients. Nine (45%) of 20 patients required at least one dose reduction and two (10%) discontinued treatment due to toxicity. There were no treatment related deaths. INTERPRETATION: This study met its primary endpoint, showing high clinical activity of pembrolizumab plus lenvatinib, but with substantial toxicity, in patients with pleural mesothelioma who had progressed after first-line nivolumab plus ipilimumab. This drug combination is promising for future studies in pleural mesothelioma. FUNDING: Merck Sharp and Dohme.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Douma LH, van der Noort V, Lalezari F, et al. Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study. Lancet Oncol. 2025. PMID: 41308680. doi:10.1016/S1470-2045(25)00514-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。